Loading…
← CockpitCompetitor Analysis › 028300.KS HLB Co., Ltd.Open in the cockpit ↗

HLB Co., Ltd.028300.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

Korean biopharma developing rivoceranib (apatinib), an oral anti-cancer drug, alongside a broader oncology and biotech pipeline.

Momentum laggard 12
Mkt cap
$2.69B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$16.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-16.7 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Close · KRW₩27,150
1D-4.1%
1W-9.2%
1M-36.9%
3M-37.1%
6M-49.0%
YTD-46.6%
1Y-46.2%
ATR %8.3%
52w lowhigh60.8% off high

What HLB does

Korean biopharma developing rivoceranib (apatinib), an oral anti-cancer drug, alongside a broader oncology and biotech pipeline.

Its value rests largely on the liver-cancer drug rivoceranib, which its US subsidiary Elevar Therapeutics is developing in combination with an immunotherapy from China's Hengrui Medicine. Approval would turn trial spending into sales and milestone income. HLB also sits at the centre of a group of other listed Korean biotech affiliates.

Products and services

  • Rivoceranib (liver/other cancers)
  • Oncology combination-therapy pipeline

Customers

  • Oncologists/hospitals (via partners)

Where it sits in the supply chain

  • Biotechnology
  • Oncology drug development
  • Global licensing/commercialization

What could go right

  • Rivoceranib FDA approval/commercial launch

What could go wrong

  • Clinical trial/FDA rejection risk
  • Single-drug pipeline concentration

Moat: narrow (IP / patents). Patented VEGFR2 inhibitor rivoceranib in late-stage global trials for liver cancer.

Headquarters: Seongnam, South Korea · Employees: 151

Named competitors

HLB at a glance

Size HLB (028300.KS) is a South Korea Health Care company (Biotechnology) with a market value of $2.69B, the 110th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩27,150 on 18 Nov 2026.

Performance Over six months the shares fell 49.0%, against -2.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 25.5% over the last twelve months (peer median +6.3%); the operating margin is -96.4% (peer median 9.0%).

Valuation It trades at 38.7× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 18).

Capital Return on invested capital runs 16.7 points below its cost of capital (6.5% WACC).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 98028300.KS 52
Six months, rebased to 100: HLB against the median of its 20 peers (local-currency closes).

HLB financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩101B₩84.2B₩68.1B₩42.9B₩180B
Revenue growth—+24%+59%-76%—
Gross profit₩38.0B₩24.9B₩8.44B-₩8.08B₩51.3B
EBITDA-₩91.0B-₩94.0B-₩112B-₩106B-₩58.3B
Net income-₩159B-₩221B-₩92.0B-₩188B-₩78.2B
Free cash flow-₩93.4B-₩110B-₩134B-₩118B-₩73.6B
Capital expenditure₩2.95B₩17.5B₩27.1B₩7.06B₩12.6B
Total debt₩320B₩285B₩160B₩62.7B₩130B

Quarterly statements and history in the cockpit →

HLB competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%6887MBX9688XNCRBAVA6882782228300142RUBICONDNLITLXADMAXERS300255RCUSVIRPLKFTVIMIAN028300.KS6-month return →1-month return →
Up and to the right = strong over both horizons. HLB is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×20×40×68879688XNCRBAVA6882782228300142RUBICONTLXADMAXERS300255RCUSVIRP002007028300.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HLB is the large dot.

HLB competitors and peer comparison

Head to head with its named competitors (028300.KS vs 128940.KS vs 4523.T vs BAYN.DE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
HLB 028300.KS$2.69B-49%+26%-96%38.7×n/a
HanmiPharm 128940.KS$3.95B-2%+14%16%3.3×4.7%
Eisai 4523.T$9.36B+11%+11%6%1.6×10.7%
Bayer BAYN.DE$60.3B+48%0%13%2.0×n/a

How HLB compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HLB against its 20 peers (data as of 18 Nov 2026)
Measure028300.KSPeer medianRank in peer set
1-month return-36.9%-2.6%lowest of 21
6-month return-49.0%-2.0%2nd lowest of 21
Distance from 52-week high-60.8%-27.6%3rd lowest of 21
Revenue growth (TTM)+25.5%+6.3%6th highest of 18
Operating margin-96.4%9.0%4th lowest of 19
EV / Sales38.7×6.0×2nd most expensive of 18
ROIC minus cost of capital-16.7 pp-2.9 pp5th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%

Questions

Who are HLB's main competitors?
Named competitors: Hanmi Pharm (128940.KS), Eisai (lenvatinib) (4523.T), Bayer (sorafenib) (BAYN.DE). The cockpit's measured peer set (industry) also includes Sunshine Lake Pharma (6887.HK), MBX Biosciences (MBX), Zai Lab (9688.HK), Xencor (XNCR), Bavarian Nordic A/S (BAVA.CO), Xiamen Amoytop Biotech (688278.SS).
Is HLB expensive compared with its peers?
On ev / sales it trades at 38.7× against a peer median of 6.0×, 2nd most expensive of 18 in its peer set.
How has HLB stock performed?
Over six months to 18 Nov 2026 the shares returned -49.0% against -2.0% for the median peer; over one year -46.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.